In our study, after myeloma cell lines were treated in the presence of rapamycin extended to 48 h, two important mTORC2 downstream targets—Akt S473 and T450 phosphorylation—were inhibited, which made us believe that myeloma cells mTORC2 pathway was inhibited after chronic exposure to rapamycin. Here, AKT1 is linked to plasma cell myeloma.